國家衛生研究院 NHRI:Item 3990099045/10042

NHRI > National Institute of Infectious Diseases and Vaccinology > Others > Conference Papers/Meeting Abstract > Item 3990099045/10042

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10042

Title:	Development of a synthetic virus for enterovirus A71 vaccine candidate
Authors:	Wang, JR;Cheng, CK;Huang, SW
Contributors:	Division of Infectious Diseases
Abstract:	Human enterovirus A71 (EV-A71) has become an emergent infectious disease worldwide most notably in Asia. EV-A71 infection occasionally causes neurological diseases with pulmonary edema, which is fatal for children. Based on phylogenetic analysis of VP1 protein coding sequences, most EVA71 isolates are classified into genotypes A, B and C, while some isolates belong to the recently discovered genotypes D, E, and F. Synthetic viruses have been applied to produce vaccine seed viruses for influenza virus and others. To produce a synthetic virus of EV-A71, we used 4643-TW-98 (genotype C2) as the template (r4643), de novo synthesized the capsid protein genome of genotype C4 and introduced into the cDNA clone of r4643 to produce reverse genetics virus (r4643-C4VP). We then compared the viral properties of this r4643-C4VP with parental r4643 and native 4643 virus. The r4643-C4VP showed relatively smaller plaque morphology than native 4643, but the virus-induced cytopathic effect was similar to both r4643 and native 4643. Synthetic reverse genetics viruses and native virus showed no significant difference in growth rate in both RD and Vero cell lines. In addition, mouse anti-r4643 and anti- r4643-C4VP sera showed similar neutralizing antibody titers against both r4643-C4VP and r4643 viruses, suggesting that both viruses had similar antigenicity. Furthermore, both antisera had similar neutralization activity to different genotypes of EV-A71, including genotypes B2, B4, B5, C2, and C4. Collectively, these results prove that the synthetic virus could be applied to EV-A71 vaccine seed candidate which will contribute to next generation vaccine development.
Date:	2016-08
Relation:	European Journal of Immunology. 2016 Aug;46(Suppl. 1):1226-1227.
Link to:	http://dx.doi.org/10.1002/eji.201670200
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0014-2980&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000383610402869
Appears in Collections:	[Others] Conference Papers/Meeting Abstract

Files in This Item:

File	Description	Size	Format
ISI000383610402869.pdf		189Kb	Adobe PDF	404	View/Open

Loading...